Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 42

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Study on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Urticaria chronic

Not recruiting

Study on Long-Term Safety of Briquilimab for Patients with Chronic Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

HIV infection

Not recruiting

Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

Myelofibrosis

Not recruiting

Study on the Safety and Effectiveness of Fedratinib and Azacitidine for Patients with Accelerated Phase Myelofibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Cough

Not recruiting

Study on the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) for Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Taplucainium Chloride
  • Sponsor:Nocion Therapeutics Inc.

Polycythaemia vera+3

Not recruiting

Study of Gandotinib for Patients with Myeloproliferative Neoplasms, Myelofibrosis, Essential Thrombocythemia, or Polycythemia Vera

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gandotinib
  • Sponsor:Eli Lilly & Co.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.